Literature DB >> 1176605

Passive transfer of immunity into leprosy patients by transfusion of lymphocytes and by transfusion of Lawrence's transfer factor.

K Saha, M M Mittal, H B Maheshwari.   

Abstract

About 1,200 million viable lymphocytes from normal but lepromin- and tuberculin-positive human beings were transfused in four patients of lepromatous and one of tuberculoid leprosy three times at monthly intervals. Three patients of lepromatous leprosy suffered from erythema modosum, whereas the other two developed severe reaction whenever put on the smallest dose of dapsone. In one patient of lepromatous leprosy, minimal improvement or none was observed, whereas in the remaining three cases of lepromatous and one of tuberculoid leprosy, clinical, bacteriological, as well as histological improvement occurred. Two of the five patients started to tolerate the dapsone during the period of study. The present study indicates that immunotherapy might have a definite role in the management of the disease especially in cases with erythema nodosum. Lawrence factor, prepared from leucocytes of normal donors, was transfused three times into four lepromatous leprosy patients who were intolerant to anti-leprosy drugs. The donors were healthy but were tuberculin and lepromin (Mitsuda) positive. The clinical, histological, bacteriological (morphological index), and immunological assessments of the patients were performed before and 5 months after starting the immunotherapy. In two patients conversion of Mitsuda reaction occurred, but there was no appreciable improvement in the clinical, histologic, and bacteriologic status of these patients.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1176605      PMCID: PMC275059          DOI: 10.1128/jcm.1.3.279-288.1975

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  The transfer in humans of delayed skin sensitivity to streptococcal M substance and to tuberculin with disrupted leucocytes.

Authors:  H S LAWRENCE
Journal:  J Clin Invest       Date:  1955-02       Impact factor: 14.808

2.  The staining of acid-fast bacilli in paraffin sections.

Authors:  G L Fite
Journal:  Am J Pathol       Date:  1938-07       Impact factor: 4.307

3.  Chemotherapeutic trials in leprosy. 5. A study of methods used in clinical trials in lepromatous leprosy.

Authors:  M F Waters; R J Rees; I Sutherland
Journal:  Int J Lepr Other Mycobact Dis       Date:  1967 Jul-Sep

Review 4.  Transfer factor and other mediators of cellular immunity.

Authors:  H S Lawrence; F T Valentine
Journal:  Am J Pathol       Date:  1970-09       Impact factor: 4.307

5.  A study of cell mediated immunity in leprosy: changing trends in the immunological spectrum of the disease.

Authors:  K Saha; M M Mittal
Journal:  Clin Exp Immunol       Date:  1971-06       Impact factor: 4.330

6.  Lymphocyte-mediated modification of blood-derived macrophage function in vitro; inhibition of growth of intracellular mycobacteria with lymphokines.

Authors:  T Godal; R J Rees; J O Lamvik
Journal:  Clin Exp Immunol       Date:  1971-04       Impact factor: 4.330

7.  A logarithmic index of bacilli in biopsies. 2. Evaluation.

Authors:  D S Ridley
Journal:  Int J Lepr Other Mycobact Dis       Date:  1967 Apr-Jun

8.  Normal lymphocyte transfer tests in leprosy.

Authors:  K Saha; M M Mittal
Journal:  Clin Exp Immunol       Date:  1970-06       Impact factor: 4.330

9.  Classification of leprosy according to immunity. A five-group system.

Authors:  D S Ridley; W H Jopling
Journal:  Int J Lepr Other Mycobact Dis       Date:  1966 Jul-Sep

10.  Lymphocyte transfer tests in cancer patients and healthy people.

Authors:  A G Levin; D G Miller; C M Southam
Journal:  Cancer       Date:  1968-09       Impact factor: 6.860

View more
  1 in total

1.  Induction and treatment of anergy in murine leprosy.

Authors:  Mario Juarez-Ortega; Víctor G Hernandez; Patricia Arce-Paredes; Enrique B Villanueva; Miguel Aguilar-Santelises; Oscar Rojas-Espinosa
Journal:  Int J Exp Pathol       Date:  2014-12-21       Impact factor: 1.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.